Chapter 33
Induction of Apoptosis in Liver Tumors
Markus Selzner MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Markus Selzner MD
Department of Surgery, Multiorgan Transplant Program, Toronto General Hospital, Toronto, Ontario, Canada
Search for more papers by this authorPierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorMarkus Selzner MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Markus Selzner MD
Department of Surgery, Multiorgan Transplant Program, Toronto General Hospital, Toronto, Ontario, Canada
Search for more papers by this authorPierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Apoptosis
-
Inhibition of the apoptotic pathway in cancer cells
-
Necrosis
-
Conclusion
-
Strategies to induce a poptosis in tumor cells
-
Self-assessment questions
-
References
-
Self-assessment answers
References
- Makin G, Hickman J. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000; 301: 143–52.
- Budman D, Berry D, Cirrincione C, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998; 90: 1205–11.
- Glücksmann A. Cell deaths in normal vertebrate develpment. Biol Rev 1951; 26: 59–86.
- Saunders J. Deaths in embryonic systems. Science 1966; 154: 604–12.
-
Kerr J. Shhrinkage necrosis: a distinct mode of cellular death. J Pathol 1971; 105: 13–20.
10.1002/path.1711050103 Google Scholar
- Reed J. Dysregulation of apoptosis in cancer. J Clin Oncol 2000; 17: 2941–53.
- Kanzler S, Galle PR. Apoptosis and the liver. Semin Cancer Biol 2000; 10: 173–84.
- Roy S. Caspases at the heart of the apoptotic cell death pathway. Chem Res Toxicol 2000; 13: 961–2.
- Kaufmann S, Gores G. Apoptosis in cancer: cause and cure. BioEssay 2000; 22: 1007–17.
- Ding H, Fisher D. Mechanisms of p53-mediated apoptosis. Crit Rev Oncogen 1998; 9: 83–98.
- Mott JL, Gores GJ. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology 2007; 46: 906–11.
- Selzner M, Bielawaska A, Morse M, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61: 1233–40.
- Dahm F, Bielawska A, Nocito A, et al. Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice. Br J Cancer 2008; 98: 98–105.
- LaCasse E, Baird S, Korneluk R, MacKenzie A. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–59.
- Selzner M, Rüdiger H, Sindram D, et al. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000; 32: 1280–8.
- Diao J, Garces R, Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 2001; 12: 189–205.
- Chen GG, Lai PB, Chan PK, et al. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur J Cancer 2001; 37: 1695–702.
- Li D, Chen X, Zhang W. The inhibition of apoptosis of hepatoma cells induced by HBx is mediated by up-regulation of survivin expression. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 383–6.
- Kalra N, Kumar V. c-Fos is a mediator of the c-myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway. J Biol Chem 2004; 279: 25313–9.
- Ikeguchi M, Ueda T, Sakatani T, et al. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002; 11: 33–40.
- Ogawa K, Yasumura S, Atarashi Y, et al. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol 2004; 40: 278–84.
- Villunger A, Strasser A. Does death receptor signaling play a role in tumorgenesis and cancer therapy. Oncol Res 1998; 10: 541–50.
- Pitti R, Marsters S, Lawrence D, et al. Genomic amplifi cation of a decoy receptor for fas ligand in lung and colon cancer. Nature 1998; 396: 699–703.
- Joseph B, Ekedahl J, Sirzen F, et al. Differences in the expression of pro-caspase in small cell and non-small cell lung carcinoma. Biochem Biophys Res Comm 1999; 262: 381–7.
- Klohn P, Bitsch A, Neumann H. Mitochondrial permeability transition is altered in early stages of carcinogenesisof 2-acetylaminofl uorene. Carcinogenesis 1998; 19: 1185–90.
- Reed J. Bcl-2 family proteins. Oncogene 1998; 17: 3225–36.
- JäätteläM. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999; 248: 30–43.
- Berghella A, Pellegrini P, Contasta I, et al. Bcl-2 and drugs used in the treatment of cancer: new strategies of biotherapie which should not be underestimated. Cancer Biother 1998; 13: 225–37.
- Soini Y, Virkajarvi N, Lehto V, Paako P. Hepatocellular carcinoma with high proliferation index and a low degree of apoptosis and necrosis. Br J Cancer 1996; 73: 1025–30.
- Terada T, Nakanuma Y. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53 in human cholangiocarcinoma and hepatocellular carcinomas. Pathol Int 1996; 46: 764–70.
- Soengas M, Alacron R, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284: 156–9.
- Asker C, Wiman K, Selivanova G. p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Comm 1999; 265: 1–6.
- Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006; 66: 4766–73.
- Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080–5.
- Kaufmann S, Earnshaw W. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42–9.
- Hieber U, Heim M. Tumor necrosis factor for the treatment of malignancies. Oncology 1994; 51: 142–53.
- Ogasawara J, Watanabe-Fukunaga R, Adachi A, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–9.
- Cotter F. Antisense therapy of hematologic malignanvies. Semin Hematol 1999; 36: 9–14.
- Ambrosini G, Adida C, Sirugo G, Altieri D. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177–82.
- Dindo D, Dahm F, Szulc Z, et al. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol Cancer Ther 2006; 5: 1520–9.
- Di Paola M, Cocco T, Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry 2000; 39: 6660–8.
- Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006; 5: 200–8.
- Ruvolo PP, Deng X, Ito T, et al. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 1999; 274: 20296–300.
- Colell A, Garcia-Ruiz C, Mari M, Fernandez-Checa JC. Mitochondrial permeability transition induced by reactive oxygen species is independent of cholesterol-regulated membrane fl uidity. FEBS Lett 2004; 560: 63–8.
